Johnson & Johnson (NYSE:JNJ) shares ticked up today on first-quarter results that were mixed compared to the consensus forecast.
The New Brunswick, New Jersey-based company posted profits of $5.1 billion, or $1.93 per share, on sales of $23.4 billion in the first quarter for a 16.9% bottom-line slide on sales growth of nearly 5%.
Adjusted to exclude one-time items, earnings per share were $2.67, 6¢ ahead of Wall Street, where analysts were looking for sales of $23.7 billion.
Johnson & Johnson’s only segment to see sales decline was its consumer health arm, while pharmaceuticals produced the highest revenue growth, rising 6.3%, with the company’s COVID-19 vaccine contributing to that year-over-year increase.
“Our first-quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds,” Johnson & Johnson CEO Joaquin Duato said in a news release. “I am incredibly proud of Johnso…